Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 4Phase 3 3Phase 1/2 3Phase NA 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 13Lymphoma 12Neuroblastoma 10Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Immunoglobulin Light-chain Amyloidosis 8Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5Uveal Melanoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia 3Amyloidosis 3Neoplasm Metastasis 2Hodgkin Disease 2Ganglioneuroblastoma 2Venentoclax 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Histologic Type 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × Melphalan × Clear all
NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00003789 2013-07-16

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

National Cancer Institute (NCI)

Phase 3 Completed
216 enrolled
Dermatologic

Melanoma

NCT00001296 2008-03-04

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
122 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡